These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38917674)

  • 1. Risk of drug-related death associated with co-prescribing of gabapentinoids and Z-drugs among people receiving opioid-agonist treatment: A national retrospective cohort study.
    Glancy M; Palmateer N; Yeung A; Hickman M; Macleod J; Bishop J; Barnsdale L; Trayner KM; Priyadarshi S; Wallace J; Hutchinson S; McAuley A
    Psychiatry Res; 2024 Sep; 339():116028. PubMed ID: 38917674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records.
    Macleod J; Steer C; Tilling K; Cornish R; Marsden J; Millar T; Strang J; Hickman M
    PLoS Med; 2019 Nov; 16(11):e1002965. PubMed ID: 31770388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-fatal overdose risk associated with prescribing opioid agonists concurrently with other medication: Cohort study conducted using linked primary care, secondary care and mortality records.
    Domzaridou E; Carr MJ; Millar T; Webb RT; Ashcroft DM
    Addiction; 2023 Dec; 118(12):2374-2383. PubMed ID: 37536685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017.
    Vold JH; Skurtveit S; Aas C; Chalabianloo F; Kloster PS; Johansson KA; Fadnes LT
    BMC Health Serv Res; 2020 Apr; 20(1):352. PubMed ID: 32334602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription drugs with potential for misuse in Irish prisons: analysis of national prison prescribing trends, by gender and history of opioid use disorder, 2012 to 2020.
    Durand L; Keenan E; O'Reilly D; Bennett K; O'Hara A; Cousins G
    BMC Psychiatry; 2023 Oct; 23(1):725. PubMed ID: 37803285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality among individuals prescribed opioid-agonist therapy in Scotland, UK, 2011-20: a national retrospective cohort study.
    McAuley A; Fraser R; Glancy M; Yeung A; Jones HE; Vickerman P; Fraser H; Allen L; McDonald SA; Stone J; Liddell D; Barnsdale L; Priyadarshi S; Markoulidakis A; Hickman M; Hutchinson SJ
    Lancet Public Health; 2023 Jul; 8(7):e484-e493. PubMed ID: 37295452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017.
    Vold JH; Aas C; Skurtveit S; Odsbu I; Chalabianloo F; Halmøy A; Johansson KA; Fadnes LT
    BMC Psychiatry; 2020 Mar; 20(1):119. PubMed ID: 32164615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: A retrospective cohort study.
    Kennedy MC; Crabtree A; Nolan S; Mok WY; Cui Z; Chong M; Slaunwhite A; Ti L
    PLoS Med; 2022 Dec; 19(12):e1004123. PubMed ID: 36454732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription opioid use among people with opioid dependence and concurrent benzodiazepine and gabapentinoid exposure: An analysis of overdose and all-cause mortality.
    Bharat C; Gisev N; Barbieri S; Dobbins T; Larney S; Buizen L; Degenhardt L
    Int J Drug Policy; 2024 Jan; 123():104287. PubMed ID: 38088003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland.
    Torrance N; Veluchamy A; Zhou Y; Fletcher EH; Moir E; Hebert HL; Donnan PT; Watson J; Colvin LA; Smith BH
    Br J Anaesth; 2020 Aug; 125(2):159-167. PubMed ID: 32571568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
    Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
    Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study.
    Abrahamsson T; Berge J; Öjehagen A; Håkansson A
    Drug Alcohol Depend; 2017 May; 174():58-64. PubMed ID: 28315808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
    Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
    JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent use of prescription gabapentinoids with opioids and risk for fall-related injury among older US Medicare beneficiaries with chronic noncancer pain: A population-based cohort study.
    Chen C; Winterstein AG; Lo-Ciganic WH; Tighe PJ; Wei YJ
    PLoS Med; 2022 Mar; 19(3):e1003921. PubMed ID: 35231025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017.
    Vold JH; Aas C; Skurtveit S; Odsbu I; Chalabianloo F; Reutfors J; Halmøy A; Johansson KA; Fadnes LT
    BMJ Open; 2020 Aug; 10(8):e036860. PubMed ID: 32771988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.
    Pearce LA; Min JE; Piske M; Zhou H; Homayra F; Slaunwhite A; Irvine M; McGowan G; Nosyk B
    BMJ; 2020 Mar; 368():m772. PubMed ID: 32234712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Race and Ethnicity With Postoperative Gabapentinoid and Opioid Prescribing Trends for Older Adults.
    Bongiovanni T; Gan S; Finlayson E; Ross JS; Harrison JD; Boscardin WJ; Steinman MA
    J Surg Res; 2024 Jun; 298():47-52. PubMed ID: 38554545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
    Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
    Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in overdose deaths involving gabapentinoids and Z-drugs in the United States.
    Powell D; Shetty KD; Peet ED
    Drug Alcohol Depend; 2023 Aug; 249():109952. PubMed ID: 37301069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.